CNC

Business profile & competitive position

Centene Corp. (CNC) operates in the Healthcare sector, specifically the Medical - Healthcare Plans industry. It describes itself as the nation's largest managed care company focused on underserved populations, delivering Medicaid, Medicare Advantage, Prescription Drug Plans (PDP), Medicare Supplement products, and commercial plans through the Health Insurance Marketplace. The company runs local brands such as Health Net and Ambetter, supported by national infrastructure, and connects members to supplemental services including food, housing, utilities, and transportation assistance.

The scale figures are concrete: as of December 31, 2025, Centene reported total membership of 27.6 million, split among 12.5 million Medicaid members, 5.5 million Marketplace members, and 8.1 million stand-alone PDP members. For 2025, total revenues reached $194.8 billion, with Medicaid contributing 57%, Commercial 21%, Medicare 19%, and Other 3%. It also holds the number-one market position as the largest Medicaid insurer, largest Marketplace insurer, and largest stand-alone PDP provider in the United States.

That scale suggests significant membership density and payer leverage, which are classic competitive advantages in managed care. However, the margin and return figures tell a different part of the story. Centene's net margin is negative 2.6% and return on equity (ROE) is negative 24.0%. Those numbers imply that, despite its leadership in covered lives, the company is currently earning less than its cost of equity on a trailing basis and is not converting revenue into net income. Scale alone is not translating into current profitability strength, so the moat is better understood as a market-share moat rather than a high-return one at this stage.

Financial posture

Centene's current financial posture is dominated by negative trailing profitability metrics. The stock trades with a market capitalization of $30.9 billion and a trailing P/E ratio of negative 6.0, which reflects that reported earnings have been negative rather than a conventionally priced growth multiple. The net margin of negative 2.6% and ROE of negative 24.0% reinforce that the business has been losing money on the bottom line in the most recent reporting window.

At the same time, the company is not without cash-generation capacity: the 2025 10-K notes operating cash flow of $5.1 billion, which shows the underlying insurance operations are producing cash even while GAAP net income is under pressure. The stock currently sits at $62.49, with a 14-day RSI of 42.3 and a 50-day exponential moving average of $64.41, so price is slightly below that near-term trend benchmark. Beta is 1.11, meaning the stock has historically moved a bit more than the broader market on average.

Valuation here is therefore a tale of two lenses. A negative P/E and negative margins make traditional earnings-based valuation difficult, yet the company retains a large revenue base and positive operating cash flow. Investors evaluating the ticker need to reconcile those trailing accounting losses with the underlying membership scale and cash generation.

Strategic priorities & outlook

Centene's most recent SEC 10-K filing outlines several operational priorities. The first is continued refinement of the Medicare footprint so that it overlaps more closely with Medicaid operations, while expanding Dual-Eligible Special Needs Plan (D-SNP) offerings as a long-term growth driver. Management has identified the D-SNP opportunity as an enterprise-level focus, including integrated products aligned with CMS requirements that phase in through 2030.

On the policy front, the company intends to advocate for legislation and regulation that preserves affordable Medicaid and Marketplace coverage, as well as cost-effective, high-quality care for PDP members. Operationally, Centene is implementing 2026 corrective Marketplace pricing actions in states that cover 95% of its Marketplace membership, and it plans to expand Ambetter Health Solutions / ICHRA-compatible off-exchange coverage from 6 states to 13 states.

Corporate simplification is also part of the agenda: in December 2025, Centene signed a definitive agreement to divest the remaining Magellan Health businesses. The 2025 revenue mix—57% Medicaid, 21% Commercial, 19% Medicare, and 3% Other—shows that Medicaid remains the core economic engine, while Medicare and D-SNP expansion represent the primary levers for changing the growth and margin profile over time.

Macro & geopolitical exposure

As a managed care company in the Medical - Healthcare Plans industry, Centene's exposure is primarily regulatory and fiscal rather than trade- or commodity-driven. The most important macro factor is Medicaid funding and eligibility policy, since Medicaid represented 57% of 2025 revenue. Changes in federal matching formulas, state budget pressures, or eligibility redetermination rules can materially affect member rolls and premium revenue.

Medicare reimbursement policy is another key exposure, particularly CMS rules for Medicare Advantage, PDP, and D-SNP products through 2030. The 10-K explicitly ties Centene's D-SNP integration efforts to CMS requirements, so any change in those standards would directly affect product design and profitability. Marketplace regulation, including subsidies, premium rating rules, and the viability of off-exchange and ICHRA alternatives, drives the commercial segment.

Broadly, the industry also faces exposure to healthcare cost inflation, medical loss ratio requirements, interest rates, and political shifts around the Affordable Care Act. Because beta is 1.11, the stock also carries slightly above-market sensitivity to overall equity risk sentiment, though day-to-day price movements are usually more sensitive to earnings and regulatory headlines than to commodity or currency moves.

Recent developments

Recent headlines have echoed both investment-community framing and operational community engagement. On September 25, 2026, Zacks published "Here's Why Centene (CNC) is a Strong Value Stock," highlighting how sell-side commentary is classifying the stock through a value lens. One day earlier, on September 24, 2026, Zacks also featured CNC in "Best Growth Stocks to Buy for September 24th," showing that the same research house has simultaneously discussed the name in growth-oriented coverage.

On the operating-company side, Health Net—Centene's California-based subsidiary—was in the news on September 22, 2026. A PR Newswire release that day announced special assistance for members and providers affected by statewide weather events and the Robin Lane sewage spill in Lake County. The same day, another PR Newswire release reported that Stockton seniors gained access to 76 affordable homes through a $3 million investment by Health Net. These items illustrate Centene's emphasis on local-brand community engagement and supplemental social-support programs, consistent with its broader model of serving underserved populations.

Earnings behavior & post-earnings drift

Centene has delivered a strong earnings-beat record over the last eight reported quarters, beating estimates in 7 of 8 quarters for a beat rate of 88%. The average earnings surprise across those quarters is 63.1%. That is a high surprise rate, indicating that consensus estimates have frequently understated the company's reported EPS.

Post-earnings price behavior, however, is more nuanced. The average 5-day price move following the past eight earnings reports is 2.83%, classified as an upward drift. Looking at the four most recent quarters:

• On July 28, 2026, Centene reported EPS of $2.51 versus an estimate of $1.09, a 130.3% surprise. The stock fell 3.27% the next day but rose 0.25% over the following five days.
• On April 28, 2026, EPS came in at $3.37 versus $2.23 estimated, a 51.1% surprise. The stock jumped 8.9% the next day and extended that gain to 6.88% over the following five days.
• On February 6, 2026, EPS was -$1.19 versus an estimate of -$1.22007, a 2.5% surprise. The next-day move was -1.09%, but the five-day drift was +5.51%.
• On October 29, 2025, EPS was $0.50 versus an estimate of -$0.14475, a 445.4% surprise. The stock still fell 6.21% the next day and was down 1.34% over the following five days.

The pattern suggests the market has digested beats in varied ways: a strong beat can produce an immediate rally, a delayed drift, or even a selloff if forward guidance or margins disappoint. The next scheduled earnings release is October 27, 2026, before the market open, with consensus EPS at $0.09574. Traders watching this name should note that the unofficial consensus—and the company's ability to beat it—has historically been only one part of the post-release price equation.

For a deeper dive into how institutional analysts are currently weighing Centene's strategic turnaround, Medicaid exposure, and upcoming October 27 earnings report, review the full institutional verdict and consensus breakdown on the ticker page.